Ligand Pharmaceuticals (LGND) vs Veradermics (MANE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Ligand Pharmaceuticals is the larger company by market cap ($6.04 billion vs $5.62 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LGND | MANE |
|---|---|---|
| Share price | $302.95 | $134.47 |
| Market cap | $6.04B | $5.62B |
| 1-day change | +2.69% | +6.19% |
| YTD return | +56.03% | — |
| 1-year return | +59.90% | — |
| 5-year return | +263.03% | — |
| P/E ratio (TTM) | 31.92 | — |
| Forward P/E | 25.35 | — |
| EPS (TTM) | $9.49 | $-4.24 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $268.09M | — |
| Revenue growth (YoY) | +60.40% | — |
| Net income (latest FY) | $124.45M | $-70.00M |
| Operating margin | 15.29% | — |
| Net margin | 46.42% | — |
| 52-week high | $326.63 | $136.72 |
| 52-week low | $175.89 | $32.00 |
| Distance from 52-week high | -7.25% | -1.65% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +13.63% | +21.59% |
| Average volume | 258.59K | 779.41K |
| Shares outstanding | 19.94M | 41.78M |
| Employees | 47 | 37 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Ligand Pharmaceuticals
LGND stock →Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 47 employees
About Veradermics
MANE stock →Veradermics, Incorporated, a clinical-stage biopharmaceutical company, focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children.
Health Care · Biotechnology: Pharmaceutical Preparations · 37 employees
LGND vs MANE FAQ
Which is bigger, Ligand Pharmaceuticals or Veradermics?
Ligand Pharmaceuticals (LGND) is larger, with a market capitalization of $6.04B compared with $5.62B for Veradermics (MANE).
Are Ligand Pharmaceuticals and Veradermics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.